COMPASS Pathways plc (FRA:5Y6)

Germany flag Germany · Delayed Price · Currency is EUR
4.560
+0.440 (10.68%)
At close: Dec 4, 2025
12.32%
Market Cap 467.66M
Revenue (ttm) n/a
Net Income (ttm) -202.26M
Shares Out n/a
EPS (ttm) -2.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 413
Average Volume 73
Open 4.300
Previous Close 4.120
Day's Range 4.240 - 4.560
52-Week Range 2.100 - 6.850
Beta n/a
RSI 47.79
Earnings Date Feb 26, 2026

About COMPASS Pathways

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, th... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2020
Employees 166
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 5Y6
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.